Context Therapeutics Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Unaudited consolidated financial statements; filed November 9, 2023.
Business context and outlook
Context is a pre-revenue biopharmaceutical company developing medicines for solid tumors. Following its March 2023 decision to discontinue ONA-XR, the company is prioritizing CTIM-76, a preclinical anti-CD3/CLDN6 bispecific antibody. IND-enabling studies were underway, and management expected to submit an IND application to the FDA in late Q1 2024. The filing also describes additional preclinical data presented at a November 2023 scientific meeting, after quarter-end.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | No revenue | No revenue | No revenue | No revenue |
| Research and development expense | $4.49 million | $2.08 million | $12.48 million | $4.95 million |
| General and administrative expense | $1.70 million | $1.97 million | $5.66 million | $6.05 million |
| Net loss | $5.87 million | $3.85 million | $17.19 million | $11.28 million |
| Net loss per share | $0.37 | $0.24 | $1.08 | $0.71 |
| Operating cash used | Not separately stated | Not separately stated | $13.82 million | $9.62 million |
At September 30, 2023, cash and cash equivalents were $21.68 million, down from $35.50 million at December 31, 2022. Total assets were $22.99 million, total liabilities $4.60 million, and stockholders’ equity $18.38 million. The filing reports no debt or credit facility. No meaningful operating margin is reported, given the absence of revenue and ongoing operating losses.
Material changes and notable items
- Q3 R&D expense increased 116% year over year, driven principally by CTIM-76 contract manufacturing and preclinical work. Nine-month R&D expense rose 152% as CTIM-76 IND-enabling activity ramped up.
- Q3 net loss increased 52% year over year; nine-month net loss increased 52%. Higher interest income partly offset operating losses.
- ONA-XR R&D costs declined after the program was discontinued. Q3 included a negative $17,363 ONA-XR expense, reflecting closeout costs below the amount previously estimated; the company said it did not expect future material ONA-XR expenses.
- Operating cash use increased to $13.82 million for the first nine months, from $9.62 million in the comparable 2022 period. There were no investing or financing cash flows in the 2023 period.
- At September 30, 2023, 15,966,053 common shares were outstanding. The company also disclosed 5.86 million warrants and 2.24 million stock options outstanding; these potential shares were excluded from diluted loss per share as anti-dilutive.
Liquidity, risks, and contingencies
Management stated that the $21.7 million cash balance was expected to fund operations into late 2024, but the financial statements also conclude that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months from issuance. The company says it will need additional capital and has no committed financing; funding may come from equity, debt, collaborations, or other arrangements, with no assurance it will be available on acceptable terms. Without it, development or operations may need to be delayed, reduced, or discontinued.
Key execution risks include CTIM-76’s preclinical and clinical development, regulatory and manufacturing progress, reliance on third-party research and manufacturing providers, and the need to finance continuing operations. The Integral Molecular license includes potential remaining development and regulatory milestones of approximately $55 million, sales milestones up to $130 million, and royalties up to 12% of net sales. No material legal proceedings were reported. Management said disclosure controls were effective and there were no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether financing is secured in time to address the disclosed going-concern uncertainty, and how actual cash runway compares with management’s late-2024 estimate.
- Whether the planned late-Q1 2024 CTIM-76 IND submission occurred, and whether clinical development milestones, costs, or timing changed.
- Whether CTIM-76 manufacturing, preclinical results, or regulatory preparation require more spending than anticipated.
- How the ONA-XR discontinuation affects any remaining contractual obligations, including the Tyligand and Integral agreements.
- Potential dilution and financing terms, considering outstanding options and warrants and the company’s stated need for additional capital.